Table 3.
Overall Survival estimates by disease and disease status subgroups, stratified by age at autoHCT
| Disease/Disease Status at HCT | 1994–1995 | 1996–1997 | 1998–1999 | 2000–2001 | 2002–2003 | 2004–2005 | Ptrend |
|---|---|---|---|---|---|---|---|
| NHL in 2nd Complete Remission or 1st Chemotherapy-sensitive Relapse | All patients | ||||||
| Number of patients | 890 | 1067 | 1041 | 1020 | 946 | 1116 | |
| OS (95% CI) at 100 days post-HCT | 89 (87–91) | 90 (88–92) | 90 (88–92) | 94 (92–95) | 94 (92–95) | 95 (94–97) | <0.001 |
| OS (95% CI) at 1 year post-HCT | 68 (65–71) | 69 (66–72) | 72 (69–75) | 77 (75–80) | 78 (75–80) | 80 (77–83) | <0.001 |
| Subgroup analysis Age 20–39 yrs at time of HCT * | |||||||
| Number of patients | 177 | 159 | 152 | 132 | 87 | 111 | |
| OS (95% CI) at 100 days post-HCT | 96 (93–98) | 91 (86–95) | 97 (93–99) | 96 (92–99) | 94 (88–98) | 97 (93–99) | 0.3116 |
| OS (95% CI) at 1 year post-HCT | 76 (70–82) | 67 (59–74) | 81 (74–87) | 82 (75–89) | 82 (73–90) | 80 (71–88) | 0.0365 |
| Subgroup analysis Age 40–59 yrs at time of HCT | |||||||
| Number of patients | 551 | 640 | 622 | 572 | 516 | 585 | |
| OS (95% CI) at 100 days post-HCT | 88 (85–91) | 91 (89–93) | 90 (87–92) | 94 (92–96) | 95 (93–97) | 95 (93–96) | <0.001 |
| OS (95% CI) at 1 year post-HCT | 68 (64–72) | 74 (70–77) | 75 (71–78) | 81 (77–84) | 82 (78–85) | 80 (76–84) | <0.001 |
| Subgroup analysis Age ≥ 60 yrs at time of HCT | |||||||
| Number of patients | 133 | 233 | 237 | 294 | 316 | 400 | |
| OS (95% CI) at 100 days post-HCT | 85 (78–91) | 86 (81–90) | 86 (81–90) | 91 (88–94) | 93 (90–96) | 96 (93–97) | <0.001 |
| OS (95% CI) at 1 year post-HCT | 58 (49–66) | 57 (51–64) | 60 (53–67) | 69 (63–74) | 71 (65–76) | 79 (75–83) | <0.001 |
|
| |||||||
| NHL with No Prior Complete Remission (Induction Failure) | All patients | ||||||
| Number of patients | 522 | 564 | 587 | 691 | 390 | 318 | |
| OS (95% CI) at 100 days post-HCT | 86 (82–88) | 88 (85–90) | 87 (84–89) | 89 (86–91) | 88 (84–91) | 90 (87–93) | 0.2810 |
| OS (95% CI) at 1 year post-HCT | 67 (63–71) | 67 (63–71) | 71 (67–74) | 70 (66–73) | 68 (63–73) | 68 (62–73) | 0.7946 |
|
| |||||||
| HL in 2nd Complete Remission or 1st Chemotherapy-sensitive Relapse | All patients | ||||||
| Number of patients | 348 | 384 | 466 | 435 | 477 | 573 | |
| OS (95% CI) at 100 days post-HCT | 95 (92–97) | 95 (92–97) | 96 (94–97) | 97(95–98) | 96 (94–98) | 97 (95–98) | 0.4758 |
| OS (95% CI) at 1 year post-HCT | 86 (82–89) | 87 (84–91) | 87 (83–90) | 89 (85–92) | 90 (87–93) | 91 (88–93) | 0.1985 |
|
| |||||||
| HL with No Prior Complete Remission (Induction Failure) | All patients | ||||||
| Number of patients | 125 | 144 | 185 | 214 | 180 | 186 | |
| OS (95% CI) at 100 days post-HCT | 90 (85–95) | 89 (84–94) | 87 (82–92) | 92 (88–95) | 95 (92–98) | 93 (89–96) | 0.0667 |
| OS (95% CI) at 1 year post-HCT | 76 (68–83) | 73 (66–81) | 69 (62–76) | 77 (71–83) | 78 (71–84) | 79 (72–85) | 0.3786 |
|
| |||||||
| MM in 1st Complete or Partial Remission | All patients | ||||||
| Number of patients | 276 | 541 | 718 | 1567 | 2423 | 3192 | |
| OS (95% CI) at 100 days post-HCT | 96 (94–98) | 96 (94–98) | 96 (94–97) | 97 (96–98) | 98 (97–98) | 98 (98–99) | <0.001 |
| OS (95% CI) at 1 year post-HCT | 83 (79–88) | 84 (81–87) | 87 (85–90) | 90 (89–92) | 92 (91–93) | 92 (91–93) | <0.001 |
| Subgroup analysis Age 20–39 yrs at time of HCT | |||||||
| Number of patients | 19 | 30 | 32 | 74 | 76 | 105 | |
| OS (95% CI) at 100 days post-HCT | NE | 97 (87–100) | 100 | 100 | 99 (95–100) | 98 (95–100) | 0.8543 |
| OS (95% CI) at 1 year post-HCT | NE | 97 (87–100) | 97 (87–100) | 94 (87–98) | 95 (88–99) | 93 (87–97) | 0.8998 |
| Subgroup analysis Age 40–59 yrs at time of HCT | |||||||
| Number of patients | 218 | 384 | 505 | 961 | 1391 | 1748 | |
| OS (95% CI) at 100 days post-HCT | 97 (95–99) | 97 (95–98) | 96 (94–98) | 97 (96–98) | 98 (97–99) | 99 (98–99) | 0.0028 |
| OS (95% CI) at 1 year post-HCT | 85 (80–89) | 85 (81–89) | 88 (85–91) | 91 (89–93) | 92 (90–93) | 93 (91–94) | <0.001 |
| Subgroup analysis Age ≥60 yrs at time of HCT | |||||||
| Number of patients | 39 | 127 | 179 | 529 | 955 | 1337 | |
| OS (95% CI) at 100 days post-HCT | 92 (82–98) | 94 (90–98) | 94 (90–97) | 97 (95–98) | 97 (96–98) | 98 (97–99) | 0.045 |
| OS (95% CI) at 1 year post-HCT | 73 (57–86) | 79 (71–85) | 84 (78–90) | 89 (86–91) | 92 (90–93) | 91 (90–93) | <0.001 |
|
| |||||||
| MM in less than a Partial Remission (Minimum Response, Stable Disease, Resistant Disease) | All patients | ||||||
| Number of patients | 105 | 177 | 392 | 420 | 521 | 586 | |
| OS (95% CI) at 100 days post-HCT | 92 (85–96) | 94 (90–97) | 96 (94–98) | 96 (94–98) | 97 (95–98) | 95 (93–97) | 0.3829 |
| OS (95% CI) at 1 year post-HCT | 79 (70–87) | 79 (73–85) | 86 (82–89) | 88 (84–91) | 88 (85–91) | 87 (84–90) | 0.0857 |
| Subgroup analysis Age 40–59 yrs at time of HCT | |||||||
| Number of patients | 68 | 122 | 257 | 248 | 302 | 300 | |
| OS (95% CI) at 100 days post-HCT | 92 (84–97) | 94 (89–98) | 96 (93–98) | 95 (92–97) | 97 (95–99) | 98(97–99) | 0.0751 |
| OS (95% CI) at 1 year post-HCT | 77 (65–87) | 83 (75–89) | 86 (81–90) | 86 (81–90) | 89 (85–93) | 88 (83–91) | 0.2728 |
| Subgroup analysis Age ≥ 60 yrs at time of HCT | |||||||
| Number of patients | 28 | 42 | 117 | 161 | 194 | 269 | |
| OS (95% CI) at 100 days post-HCT | 88 (73–98) | 90 (80–97) | 97 (93–99) | 97 (94–99) | 95 (92–98) | 91 (87–94) | 0.0478 |
| OS (95% CI) at 1 year post-HCT | 79 (60–93) | 66 (51–79) | 83 (74–89) | 91 (85–95) | 85 (80–90) | 85 (80–90) | 0.0272 |
NE= not evaluable, sample size < 25 patients in this subgroup.
*
Subgroup analyses by age are presented for the highest frequency groups